$BIIB Up to date company activities and other impo
Post# of 88929
Posted On: 04/21/2014 11:30:46 AM
$BIIB Up to date company activities and other important information about $BIIB
$BIIB
DD Notes ~ http://www.ddnotesmaker.com/BIIB
##### recent news/filings ~ source: finance.yahoo.com
Mon, 21 Apr 2014 12:16:52 GMT ~ Biogen signs Factor VIII license agreement with Amunix
read full: http://finance.yahoo.com/news/biogen-signs-fa...52284.html
*********************************************************
Mon, 21 Apr 2014 12:04:00 GMT ~ 8:04 am Biogen Idec signs license agreement with Amunix for XTENylated Factor VIII
read full: http://finance.yahoo.com/news/inplay-briefing....html#biib
*********************************************************
Mon, 21 Apr 2014 12:00:00 GMT ~ Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
- Amunix Operating Inc. announced today that Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products ...
read full: http://finance.yahoo.com/news/biogen-idec-sig...00671.html
*********************************************************
Sat, 19 Apr 2014 07:24:00 GMT ~ Preview
read full: http://online.barrons.com/article/SB500014240...p;ru=yahoo
*********************************************************
Fri, 18 Apr 2014 19:04:57 GMT ~ Exclusive: Biogen prices hemophilia drug on par with older therapies
- The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide. "We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis," Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview.
read full: http://finance.yahoo.com/news/exclusive-bioge...24584.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=BIIB&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=BIIB&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BIIB/company-info
Ticker: $BIIB
OTC Market Place: Not Available
CIK code: 0000875045
Company name: Biogen Idec, Inc.
Company website: http://www.idecpharm.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/BIIB/filings
Latest financials: http://www.otcmarkets.com/stock/BIIB/financials
Latest news: http://www.otcmarkets.com/stock/BIIB/news - http://finance.yahoo.com/q/h?s=BIIB+Headlines
Major holdings: http://data.cnbc.com/quotes/BIIB/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=BIIB+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/BIIB.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=BIIB
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Biogen+Idec%2C+Inc...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...dec%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.idecpharm.com
Alexa: http://www.alexa.com/siteinfo/http://www.idecpharm.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.idecpharm.com
http://www.pennystocktweets.com/stocks/profile/BIIB
##### last known share structure ~ source: otcmarkets.com
Market Value: $78,538,437,096 a/o Apr 17, 2014
Shares Outstanding: 236,212,930 a/o Oct 21, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0005
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/BIIB
$BIIB
DD Notes ~ http://www.ddnotesmaker.com/BIIB
##### recent news/filings ~ source: finance.yahoo.com
Mon, 21 Apr 2014 12:16:52 GMT ~ Biogen signs Factor VIII license agreement with Amunix
read full: http://finance.yahoo.com/news/biogen-signs-fa...52284.html
*********************************************************
Mon, 21 Apr 2014 12:04:00 GMT ~ 8:04 am Biogen Idec signs license agreement with Amunix for XTENylated Factor VIII
read full: http://finance.yahoo.com/news/inplay-briefing....html#biib
*********************************************************
Mon, 21 Apr 2014 12:00:00 GMT ~ Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
- Amunix Operating Inc. announced today that Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products ...
read full: http://finance.yahoo.com/news/biogen-idec-sig...00671.html
*********************************************************
Sat, 19 Apr 2014 07:24:00 GMT ~ Preview
read full: http://online.barrons.com/article/SB500014240...p;ru=yahoo
*********************************************************
Fri, 18 Apr 2014 19:04:57 GMT ~ Exclusive: Biogen prices hemophilia drug on par with older therapies
- The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide. "We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis," Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview.
read full: http://finance.yahoo.com/news/exclusive-bioge...24584.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=BIIB&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=BIIB&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/BIIB/company-info
Ticker: $BIIB
OTC Market Place: Not Available
CIK code: 0000875045
Company name: Biogen Idec, Inc.
Company website: http://www.idecpharm.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/BIIB/filings
Latest financials: http://www.otcmarkets.com/stock/BIIB/financials
Latest news: http://www.otcmarkets.com/stock/BIIB/news - http://finance.yahoo.com/q/h?s=BIIB+Headlines
Major holdings: http://data.cnbc.com/quotes/BIIB/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=BIIB+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/BIIB.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=BIIB
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Biogen+Idec%2C+Inc...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...dec%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.idecpharm.com
Alexa: http://www.alexa.com/siteinfo/http://www.idecpharm.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.idecpharm.com
http://www.pennystocktweets.com/stocks/profile/BIIB
##### last known share structure ~ source: otcmarkets.com
Market Value: $78,538,437,096 a/o Apr 17, 2014
Shares Outstanding: 236,212,930 a/o Oct 21, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0005
##### business description ~ source: otcmarkets.com
IC
DD Notes ~ http://www.ddnotesmaker.com/BIIB
(0)
(0)Scroll down for more posts ▼